Insulet Corporation (PODD)

Insulet Corp.'s stock price was significantly impacted by a voluntary medical device correction in late March/early April 2026, concerning certain Omnipod 5 Pod lots due to a design defect that could cause insulin leakage, leading to a sharp sell-off. Prior to this, the company reported strong financial results, including a 31% increase in revenue for Q4 2025 and a 30.7% increase for the full year 2025, with substantial growth in total Omnipod revenue and record new customer starts.

Insulet's products experience some demand seasonality, with the fourth quarter typically seeing higher volume through wholesale with specialty pharma. Despite this, the company has consistently reported sustained global demand for its Omnipod 5 system and achieved record new customer starts across all quarters in 2025.

Insulet Corporation is a medical device company focused on simplifying insulin delivery for individuals with insulin-dependent diabetes. Their flagship product is the Omnipod Insulin Management System, a tubeless, wearable, and disposable insulin pump. The company operates on a high-margin, recurring revenue model, with disposable Pods driving the majority of its revenue and also leverages its pod-based technology for non-insulin subcutaneous drug delivery applications.

Insulet Corporation has a growing global presence, with its products available in 25 countries. The company has offices and manufacturing facilities in the United States, Canada, Europe, the Middle East, Australia, China, England, France, Germany, Malaysia, and the U.A.E.

In the past year, Insulet's brand reputation has been affected by the voluntary medical device correction concerning Omnipod 5 Pods and subsequent investigations into potential securities fraud. Prior to these issues, Insulet had a strong reputation, being recognized as the #1 most requested and #1 most prescribed Automated Insulin Delivery (AID) system in the U.S. in 2025, and achieving over 600,000 estimated active Omnipod users globally in 2025.

Insulet Corporation's ownership is primarily concentrated among institutional investors, including Vanguard Group Inc., BlackRock, Inc., Fmr Llc, Capital Research Global Investors, State Street Corp, Baillie Gifford & Co, Geode Capital Management, Llc, American Century Companies Inc, Invesco Ltd., and Clearbridge Investments, LLC.